Valeant to Lead US Dermatology Market with US$2.6 B Medicis Buyout
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 9 (Table of Contents)
Published: 11 Sep-2012
DOI: 10.3833/pdr.v2012.i9.1803 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Valeant Pharmaceuticals has agreed to acquire all of the outstanding common stock of the US dermatology company Medicis Pharmaceuticals for US$44 per share in cash...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS